Mobile

A MULTICENTER, MULTINATIONAL, SINGLE-DOSE, OPEN LABEL, RANDOMIZED, 2-WAY CROSSOVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 100/6 NEXT DPI® (FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100 µg PLU...

Update Il y a 4 ans
Reference: EUCTR2010-018947-33

A MULTICENTER, MULTINATIONAL, SINGLE-DOSE, OPEN LABEL, RANDOMIZED, 2-WAY CROSSOVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 100/6 NEXT DPI® (FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg) VERSUS THE FREE COMBINATION OF LICENSED BECLOMETHASONE DPI AND FORMOTEROL DPI IN ASTHMATIC ADOLESCENTS AND ADULTS PATIENTS

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the systemic exposure to B17MP (active metabolite of BDP) as AUC0-t, after four single inhalations of fixed combination CHF1535 100/6 NEXT DPI® (total dose: BDP 400 μg / FF 24 μg) in comparison with a free combination of BDP DPI and formoterol DPI licensed products in asthmatic adult and adolescent population.

Inclusion criteria

  • Asthma (patients aged 12-65 years)

Links